JAK2 and prostate neoplasm: Similar results were obtained by Toso et al. that showed that Pten-null senescent cells in prostatic tumors present an immunosuppressive SASP, and treatment with Jak2/STAT inhibitors modified the secretome activating anti-tumor immunity and enhancing the response to chemotherapy74.